

ALK-Abelló
Company Announcement

PRE-PEN[®], Penicillin Allergy Test Approved by Health Canada

Summary: ALK-Abelló is pleased to announce the marketing authorization of PRE-PEN[®] by Health Canada. PRE-PEN[®], a penicillin skin test reagent, received Health Canada approval on September 21, 2011.

Round Rock, TX, 2011-10-17 5:00 EDT -

ALK-Abelló is pleased to announce the marketing authorization of PRE-PEN[®] by Health Canada. PRE-PEN[®], a penicillin skin test reagent, received Health Canada approval on September 21, 2011.

PRE-PEN[®] was a widely used skin test product for over 30 years. In 2004, PRE-PEN[®] was withdrawn from the marketplace due to the lack of a dedicated penicillin manufacturing facility from the previous supplier. The loss of this product severely limited a physician's ability to test for penicillin sensitivity. In 2005, AllerQuest was formed to resurrect production of PRE-PEN[®] so that allergy specialists and hospitals could again have access to this skin test for penicillin sensitivity.

ALK-Abelló, Inc. entered into a definitive agreement with AllerQuest, LLC in 2009, to market and distribute PRE-PEN[®] penicillin skin testing products in North America. The USA launch with FDA approval occurred in September, 2009, and now marketing authorization has been received from Health Canada. AllerQuest will continue to manufacture the product in their Plainville, CT facility, which is exclusively dedicated to the production of PRE-PEN and related beta-Lactam testing products

Jose A. Moreno Toscano, President of ALK-Abelló, Inc., stated, "ALK is excited to be the exclusive distributor of PRE-PEN[®] and to bring this diagnostic tool to our Canadian customers. Our focus continues to be in providing allergy specialists with products such as PRE-PEN[®]."

PRE-PEN[®] has been assigned DIN # 00328693 by Health Canada and is currently being packaged for the Canadian market. For additional information please contact ALK's Canadian office at 1-800-663-0972.

Contact Information:

Kristina Smith
ALK-Abelló Inc.
512-251-0037
Kristina.smith@alk-abello.com

About ALK

ALK is a research driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy) – a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Further information is available at www.alk-abello.ca.

About AllerQuest, LLC

AllerQuest's mission is to develop skin test reagents to safely and accurately identify patients who are at risk for potentially life-threatening reactions to penicillin antibiotics. The company strives to ensure a reliable source of high quality test reagents to assist physicians in the diagnosis of penicillin allergy.